In line with our OVCAR and patient cell results, platinum treatment of TYK‐nu enhanced EphA2 (total and pS897) and reduced the tumor‐suppressive EphA2‐pY588 (Fig 4A), thus increasing pS897/pY588 ratio (Fig 4B; 5 μM cisplatin 8.6 ± 0.3, 10 μM cisplatin 8.0 ± 0.4‐fold increase, P ≤ 0.009). The gene discussed is EPHA2; the disease is neoplasm.